Anidulafungin/Voriconazole

阿尼芬净/伏立康唑

Report date: 2023/03/21 10:26:54

Base Information

Drug NameAnidulafungin/Voriconazole

Drug Alias NameVoriconazole/Anidulafungin伏立康唑/阿尼芬净

ClassificationSmall molecules > Heterocyclic drugs > AntibioticsSmall molecules > Heterocyclic drugs > Antifungals

Mechanisms of ActionCytochrome P450 51 inhibitors1,3-beta-glucan synthase inhibitorsLanosterol 14α-demethylase inhibitors

Targets1,3-beta-glucan synthaseLanosterol 14α-demethylaseCytochrome P450 51

Therapy Area/IndicationsAspergillosis

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

Global Highest StatusDiscontinued (Phase 3 Clinical)

Highest Status in ChinaN/A

Originator CompaniesPfizer Inc

China Registration ClassN/A

Active CompaniesN/A

Inactive CompaniesPfizer Inc

Active IndicationsN/A

Inactive IndicationsAspergillosis

ATC CodeN/A